LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,715 | -17.0% | 46,371 | -0.8% | 0.00% | – |
| Q2 2023 | $65,938 | -5.8% | 46,765 | +0.2% | 0.00% | – |
| Q1 2023 | $70,025 | +27.4% | 46,684 | 0.0% | 0.00% | – |
| Q4 2022 | $54,948 | +2647.4% | 46,684 | +1944.0% | 0.00% | – |
| Q3 2022 | $2,000 | -33.3% | 2,284 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | 0.0% | 2,284 | 0.0% | 0.00% | – |
| Q1 2022 | $3,000 | -40.0% | 2,284 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 2,284 | -3.8% | 0.00% | – |
| Q3 2021 | $6,000 | -53.8% | 2,373 | -14.4% | 0.00% | – |
| Q2 2021 | $13,000 | 0.0% | 2,773 | -53.0% | 0.00% | – |
| Q1 2021 | $13,000 | +225.0% | 5,896 | +154.6% | 0.00% | – |
| Q4 2020 | $4,000 | +33.3% | 2,316 | -23.2% | 0.00% | – |
| Q3 2020 | $3,000 | +50.0% | 3,014 | +0.6% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 2,995 | +4.7% | 0.00% | – |
| Q1 2020 | $2,000 | – | 2,861 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |